Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21208611 | 0.83 | HTR3A (0.40) | PDE10AOPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL21208554 | 0.83 | HRH4 (0.45) | PDE10AHRH4 | |
| SCHEMBL21208460 | 0.81 | HRH4 (0.40) | OPRM1OPRK1OPRL1HRH4MAPT | |
| SCHEMBL21208584 | 0.79 | PDE10A (0.35) | PDE10AOPRK1HRH4 | |
| SCHEMBL21208498 | 0.76 | HTR3E (0.41) | OPRM1OPRK1OPRL1HRH4MAPT | |
| SCHEMBL23919748 | 0.72 | ALOX15 (0.36) | OPRM1OPRK1OPRL1CDK4CDK6 | |
| SCHEMBL21208479 | 0.72 | TLR9 (0.36) | OPRM1OPRK1OPRL1HRH4CDK4 | |
| SCHEMBL21208430 | 0.71 | HRH4 (0.37) | OPRM1OPRK1OPRL1HRH4CDK4 | |
| SCHEMBL17255024 | 0.71 | TSHR (0.40) | PDE10AMAPTTSHR | |
| SCHEMBL31403195 | 0.71 | TSHR (0.40) | PDE10AMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
| US-20190233422-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233422-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | PDE10A 1165/4885OPRM1 4469/4885OPRK1 2864/4885 |
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, CASP7 | PDE10A 1580/4885OPRM1 4176/4885OPRK1 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.